What is HC Wainwright’s Forecast for MRKR FY2025 Earnings?

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Marker Therapeutics in a report released on Monday, December 8th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.95) per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Marker Therapeutics’ Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.54) EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.57. The company had revenue of $1.23 million during the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%.

Several other brokerages have also weighed in on MRKR. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday. Finally, Wall Street Zen cut Marker Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Three research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $10.17.

Marker Therapeutics Stock Up 4.9%

Shares of NASDAQ MRKR opened at $1.49 on Wednesday. The firm has a market cap of $24.84 million, a PE ratio of -1.21 and a beta of 1.35. The company’s fifty day simple moving average is $1.06 and its 200 day simple moving average is $1.22. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $5.95.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Marker Therapeutics during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP bought a new stake in shares of Marker Therapeutics during the 3rd quarter worth $33,000. Finally, Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the 2nd quarter worth $33,000. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.